Browse by ▼

GlaxoSmithKline

  • Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies

    By Mike Thiessen - May 15, 2013 | Tickers: GSK, PDLI, THRX

    California-based Theravance's (NASDAQ: THRX) announcement that it would split into two distinct companies has drawn a sharply positive reaction from investors. 

    As part of the split, the pharmaceutical company looks poised to turn its current drug-marketing joint venture with London-based GlaxoSmithKline (NYSE: GSK) into an independent firm. Meanwhile, it will create a development-focused biopharmaceutical company out of its existing R&D division. Whereas the first firm could generate long-term more »

  • Top Five Dividend Companies for Warren Buffett

    By Karin Hernandez - May 14, 2013 | Tickers: COP, GCI, GD, GE, GSK

    TheStreet.com recently ran an article outlining five companies that Warren Buffett holds in his portfolio that yield 3.0% or better. I decided to take a look at these five companies, since I love dividend companies, and to some degree I love Warren Buffett. (I like to read what he is doing, but I don’t own any of Berkshire Hathaway’s stock. I used to, but I sold more »

  • Who Benefits From This Market Moving Biotechnology Partnership?

    By Brian Nichols - May 14, 2013 | Tickers: ELN, GSK, THRX

    Back towards the end of April 2013, Theravance (NASDAQ: THRX) surprised everyone when it announced plans to split into two separate companies. The two companies will split its independent biopharmaceuticals operations and its respiratory assets (including the recently approved BREO ELLIPTA) partnered with GlaxoSmithKline (NYSE: GSK). Since this announcement, news of yet another partnership with Elan (NYSE: ELN) might leave investors confused as to the direction of the company. My more »

  • Why Did This Biotech Soar?

    By Brandy Betz - May 13, 2013 | Tickers: ELN, GSK, THRX

    Theravance (NASDAQ: THRX) shares soared over 14% early Monday upon news that Elan (NYSE: ELN) will pay $1 billion for a  quartet of development stage respiratory drugs. The payment will give Elan a cut of potential future royalties to the drugs -- most of which Theravance developed with GlaxoSmithKline (NYSE: GSK).

    What does this deal mean for the companies involved -- and is Elan getting its money’s worth?

    COPD breathes easier more »

  • Buy Individual Stocks Instead of Dividend ETFs

    By Robert Ciura - May 7, 2013 | Tickers: MMM, KO, GSK, WMT

    Exchange-traded funds are all the rage these days, and for good reason. As opposed to traditional mutual funds, ETFs trade throughout the day, and often have significantly lower fees than their mutual fund peers. In addition, investors wary of buying individual stocks find solace in the diversification these funds provide.

    In particular, ETFs focused on dividends have seen pronounced buying interest from investors. Products such as the Vanguard Dividend Appreciation more »

  • Cost Cutting Initiative to Bolster GlaxoSmithKline's Earnings

    By Kiran Gulati - May 6, 2013 | Tickers: GSK, PFE, PG

    GlaxoSmithKline (NYSE: GSK) is a pharmaceutical and healthcare company headquartered in the United Kingdom. GlaxoSmithKline is one of the largest pharmaceutical companies in the world with a market cap of $112 billion. The company was founded in 2000, as a result of a merger between Glaxo Welcome and SmithKline Beecham. Below is a snapshot of GlaxoSmithKline's fourth quarter results.

    Q4, ANALYSIS:-

    During the fourth quarter, GlaxoSmithKline’s earnings declined more »

  • Big Pharma's Kickback Conundrum

    By Leo Sun - May 1, 2013 | Tickers: GSK, NVS, PFE

    Big pharma is a controversial industry. Along with tobacco companies, they are some of the most vilified businesses in the world. On one hand, large pharmaceutical companies invest heavily in producing breakthrough medicines. Since 2000, the 31 main companies of the sector spent a combined $550 billion on research & development, creating 400 new medicines in the process.

    On the other hand, these companies have attempted to stop generic versions of more »

  • Four Companies that Are Better to Invest in Than Amazon

    By Nate Wooley - May 1, 2013 | Tickers: AMZN, CVX, GSK, ORCL, WMT

    Seriously, when will people stop buying the Amazon (NASDAQ: AMZN) hype?

    In it's earnings call for last quarter, online retailer Amazon.com reported a lower profit margin, a lower net income and indicated that it anticipates next quarter's net to run somewhere between $10 million and a loss of $340 million. Of course shares jumped 2.2%.

    Really, the hypnosis-like hold Amazon has on investors is a mystery more »

  • Is All Well With These 4 Pharmaceutical Powerhouses?

    By Nauman Aly - April 30, 2013 | Tickers: LLY, GSK, MRK

    In the world of big pharmaceuticals, investors have come to realize that dividend income is traditionally steady, while the share price may or may not move a great deal other than when a new breakthrough drug has been approved. As is the case, share price can also oftentimes struggle. Those big pharmas that can keep promising new products on the forefront - while at the same time keeping their dividend payout more »

  • Are Dividend Yields the Cure for Pharma Investors' Woes?

    By Nauman Aly - April 30, 2013 | Tickers: BMY, LLY, GSK

    As the market continues to climb, investors are beginning to see thinning dividend yields on many of their big pharma shares. But by sticking with quality - and with companies that are keeping their product pipelines full with new drugs - one can certainly find the key to not just share growth but also a nice steady income along the way.

    Keeping yields healthy

    One of the higher yielding big pharmaceutical companies more »

  • Will Merck's Dividends Continue to Produce Healthy Income for Investors?

    By Nauman Aly - April 30, 2013 | Tickers: LLY, GSK, MRK

    Throughout the years, some of the best performing pharmaceutical industry stocks have had long histories of providing healthy dividends to their stockholders. Merck (NYSE: MRK), for instance, a Big Pharma offering a number of healthcare solutions predominantly via its prescription meds, is well known for also providing a nice steady dividend income stream to its investors.


    Where Merck is headed

    In addition to its vaccines, biologic therapies, prescription drugs, and more »

  • You Don’t Have to Run a Cartel to Make Big Profits in Drugs

    By Ken McGaha - April 29, 2013 | Tickers: ABT, LLY, GSK, PFE, QCOR

    The market for prescription and over-the-counter drugs is huge and hugely profitable. With the global trend of an aging population well underway, it is nearly inevitable that demand for prescription and non-prescription drugs will rise. While much is made in the media regarding the so-called “patent cliff” faced by the large drug makers, well-placed investments now will allow investors to reap double-digit gains for years to come. Investors who are more »

  • Buy These Patent-Cliff Proof Stocks

    By Madhu Dube - April 29, 2013 | Tickers: GSK, MRK, PFE

    Patent expiration is one of the major issues faced by pharma companies, which increases the competition from generic medicines and eventually leads to downfall in their sales. Moreover, due to the long production cycle of new drug development, the R&D becomes ineffective to offset the patent cliff. I have picked up three such companies from the industry, which have significant drugs pipeline for the future. These companies have efficient more »

  • Can This New Drug Win Against Established Competitors?

    By Shas Dey - April 27, 2013 | Tickers: ABT, AMRN, GSK

    It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying about Amarin (NASDAQ: AMRN), which has a new drug out to cater to a vast number of patients in the cardiovascular realm. The phase III trial results have all been positive, yet, the presence of established competitors can leave some more »

  • FDA Recommendation Kick-Starts this Stock’s Long-Term Trend Higher

    By Brian Nichols - April 22, 2013 | Tickers: GSK, THRX

    It’s not often that I am bullish of a $3.2 billion clinical stage company. However, Theravance (NASDAQ: THRX) is definitely one that makes my “Buy” list, and here’s why:

    FDA Approval Leads to Massive Market Presence

    On Thursday shares of Theravane rallied 16.24% to create new five-year highs after the FDA advisory panel recommended approval for its once-daily COPD inhaler Breo Ellipta. As most know when more »

  • Cost Cutting Initiative to Bolster GlaxoSmithKline's Earnings

    By Kiran Gulati - April 18, 2013 | Tickers: GSK, PFE, PG

    GlaxoSmithKline Plc is a research based pharmaceutical and healthcare company. It is a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer healthcare products. GSK Plc was founded on December 27, 2000 and is headquartered in Brentford, United Kingdom.

    Market Cap ($mil)

    52 week high-low

    Average daily volume (sh)

    Price$

    Dividend Yield (%)

    Beta

    P/E TTM

    112,841

    48.55-41.68

    3869449 more »

  • Buy This Stock on Relative Weakness

    By Nathaniel Matherson - April 16, 2013 | Tickers: LLY, GSK, MRK

    Merck (NYSE: MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. Since the start of the year, the healthcare sector has performed exceptionally well, returning almost 17%. The sector has, as of now, outperformed every sector in the S&P 500 as a result of the more »

  • Sarepta Is a Gamble Worth Taking

    By Ishtiaq Ahmed - April 15, 2013 | Tickers: GSK, QCOR, SRPT

    There is always something interesting happening in the Bio-Pharma sector due to a number of firms working on several new drugs. Sarepta Therapeutics (NASDAQ: SRPT) is a biopharmaceutical company focused on developing RNA-based therapies. The company is currently working on Eteplirsen, a drug to cure Duchenne Muscular Dystrophy – it is a rare disease that mainly occurs in boys.

    The disease is caused by a mutation in a gene, called the more »

  • Two Biotech Movers with Upside Potential

    By Brian Nichols - April 11, 2013 | Tickers: GSK, RPRX, SRPT

    On Tuesday we saw several big moves in the biotechnology space, but two companies in particular are no strangers to big moves. In this piece I am looking at those two stocks to determine their outlook.

    Sarepta Therapeutics (NASDAQ: SRPT)

    The clinical stage biotechnology company Sarepta Therapeutics continued its march higher with gains of 11% on Tuesday. These gains followed study results from GlaxoSmithKline’s (NYSE: GSK) drug drisapersen for more »

  • After a Great Month, Now May be Time For a Change

    By Matthew Frankel - April 10, 2013 | Tickers: GSK, JNJ, MRK

    Since I recommended Johnson & Johnson (NYSE: JNJ) as one of the best long-term investments around, the stock has continued its climb.  For one of the lowest-volatility stocks in the market, a 14% gain so far in 2013, and an 8% move in the last month alone is huge.  With a move like this, is it still a good time to get into J&J, or have would-be investors missed the more »

  • Page 1 of 7